Is itrm a stock I should buy to double my earnings? There fda thing is next week

**Iterum Therapeutics (ITRM) is not a strong buy at this time.** Here's why: 1. **Financial Performance**: Iterum Therapeutics has reported a net loss of $5 million for the second quarter of 2024, which is a significant reduction from the previous year's net loss of $12.2 million. However, the company did not report any revenue for the quarter. This lack of revenue growth is a red flag for investors. 2. **FDA Approval Status**: The FDA approval for sulopenem, the company's key drug candidate, is pending with a PDUFA date set for October 25, 2024. While this is a potential milestone, the FDA review process can be unpredictable, and there is no guarantee of approval. 3. **Market Sentiment**: The stock has experienced a significant decline of 51.8% this year compared to the industry's decrease of 0.8%, which suggests that market sentiment is weak. 4. **Analyst Ratings**: The consensus EPS for Iterum Therapeutics is -$0.2 for the next quarter, with an average analyst price target of $1.17. This indicates that analysts do not expect the stock to perform well in the near term. 5. **Upcoming FDA Decision**: While the FDA decision is next week, the uncertainty surrounding the outcome and the potential impact on the stock price makes it a risky proposition to double your earnings. In conclusion, Iterum Therapeutics is not a stock that presents a strong buying opportunity at this time. The lack of revenue, negative earnings, and uncertain FDA approval status make it a high-risk investment. It is important to exercise caution and consider these factors before making any investment decisions.